Author: Michelle Prudhomme

Advances in Anticancer Agents in Medicinal Chemistry

Volume 2

eBook: US $39 Special Offer (PDF + Printed Copy): US $177
Printed Copy: US $157
Library License: US $156
ISSN: 2589-2819 (Print)
ISSN: 2214-4331 (Online)
ISBN: 978-1-60805-715-3 (Print)
ISBN: 978-1-60805-496-1 (Online)
Year of Publication: 2013
DOI: 10.2174/97816080549611130201


Advances in Anticancer Agents in Medicinal Chemistry is an exciting eBook series comprising a selection of updated articles previously published in the peer-reviewed journal Anti-Cancer Agents in Medicinal Chemistry. The second Volume of this eBook series gathers updated reviews on several classes of molecules exhibiting anticarcinogenic potential as well as some important targets for the development of novel anticancer drugs.

Featured Anti-cancer molecules:

  • - Marine macrolides and their biological targets
  • - Organometallic supramolecular complexes including gold-based anticancer agents, anti-cancer vaccines
  • - glyconanoparticles,
  • - isatin-based compounds,
  • - tripentone families of potential anticancer drugs

Drug targets in this volume include:

  • - selective estrogen receptor modulators,
  • - leukemia stem cells,
  • - glioblastoma cell migratory mechanisms
  • - Tyrosyl-DNA phosphodiesterase 1

Advances in Anticancer Agents in Medicinal Chemistry will be of particular interest to readers interested in anticancer drug therapy as the series provides relevant reviews written by experts in this important field.

Indexed in: Book Citation Index, Science Edition, EBSCO, Ulrich's Periodicals Directory.


In Volume 2 of the eBook series Advances in Anticancer Agents in Medicinal Chemistry are gathered chapters on several classes of molecules exhibiting anticancer potentialities as well as some important targets for the development of novel anticancer drugs.

Marine macrolides are fascinating molecules with a large number of chiral centers. In the first chapter of Volume 2, Antonio H. Daranas, José J. Fernández and colleagues discuss the potential of marine macrolides in cancer therapy. Various families of marine macrolides and their biological targets are presented. Since the discovery of cisplatin, a huge interest has been paid to metal-based complexes as anticancer drugs. The second chapter by Chang-He Zhou et al. reviews the recent research and development of organometallic supramolecular complexes as anticancer agents. Whereas in the third chapter, Dolores Fregona and colleagues develop the potential of gold-based anticancer agents, in particular gold(III)-dithiocarbamato complexes which, due to their lower toxicity compared to the platinum drugs, could provide an interesting alternative.

In the search for anticancer vaccines, recent synthetic strategies towards glycoconjugates have been developed. These strategies and the development of glyconanoparticles are reviewed by Laura Cipolla and co-workers.

Isatin is an oxidised derivative of indole. Various substituted isatins exhibiting anticancer properties have been identified in plants and microorganisms. Isatin is a simple and excellent scaffold for the construction of new compounds of biological interest. Kara L. Vine, Lidia Matesic and colleagues summarize the recent structure-activity relationship studies on isatin-based compounds as anticancer agents.

The tripentone family represents a promising class of compounds, some of them exhibiting a potent cytotoxicity towards cancer cells. In their chapter, Patrick Dallemagne and collaborators review the different synthetic routes to tripentones and the emergence of the highly cytotoxic MR22388.

Endocrine therapy targeting to estrogen receptors (ER) and especially ER alpha has been very successful in the treatment and prevention of breast cancer. Virgil C. Jordan and co-workers provide an excellent update on the potential of selective estrogen receptor modulators.

Leukemia stem cells (LSCs) are defined as a small cell population required for the initiation and maintenance of leukemia. The chapter by Shaoguang Li and collaborators gives an overview on the development of new therapeutic strategies and drugs targeting LSCs.

Glioblastoma (GBM) is an aggressive disease associated with a poor prognostic due to a rapid migration of the GBM cells. In this review, Cory Adamson and colleagues describe various potential targets that may be exploited to inhibit the migration GBM cells.

The last chapter by Yves Pommier et al. is devoted to a DNA repair protein Tyrosyl-DNA phosphodiesterase 1 (Tdp1), an enzyme implicated in the repair of irreversible Top1-DNA covalent complexes. Rationale for the development of Tdp1 inhibitors for cancer therapy is discussed.

Michelle Prudhomme
Institut de Chimie de Clermont-Ferrand ICCF
CNRS UMR 6296 24 Avenue des Landais 63177 Aubiere Cedex